BNT-161

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameBNT-161

Drug Alias NameqIRV(BioNTech/Pfizer)Quadrivalent influenza modRNA vaccine(BioNTech/Pfizer)modRNA-HA-qIRV(BioNTech/Pfizer)Influenza modRNA Vaccine(BioNTech/Pfizer)BNT-161 +[6]

ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccineVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsInfluenza, Human

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPhilippinesNew Zealand +[6]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesBiontech Se Pfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc

Inactive CompaniesBiontech Se

Active IndicationsInfluenza, Human

Inactive IndicationsN/A

Other Information

ATC CodeN/A